ELITE PHARMACEUTICALS INC /NV/ (ELTP)

Pharmaceutical Preparations · market cap $269M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Elite Pharmaceuticals Inc. (ELTP) is a small-cap pharma with 68 employees and a ~$372M market cap trading near $0.35/share. The company has two Phase 3 assets — an oxycodone/naltrexone capsule being studied for withdrawal symptoms and a separate formulation for pain — with no near-term catalysts disclosed and no sell-side analyst coverage.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

No pipeline data.

Price & technical context

3-month

-33.3%

6-month

-33.3%

12-month

-64.7%

52-wk range

$0.24–$0.68

vs 50-day MA

-20.9%

vs 200-day MA

-36.0%

Realized vol

54.3%

Max drawdown

-68.8%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ELTP (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.